Anthony Killeen, MD, PhD

Ellis S. Benson Professor, Department of Laboratory Medicine and Pathology

Anthony Killeen

Contact Info

Office Phone 612-625-5443

Fax 612-486-9464

Mailing Address:
MMC 609 Mayo
420 Delaware SE
Minneapolis, MN 55455

Ellis S. Benson Professor, Department of Laboratory Medicine and Pathology

Laboratory Director, Advanced Research and Diagnostic Laboratory


University College, Galway, Ireland, 1983

Hennepin County Medical Center and Mount Sinai Hospital (Internal Medicine), 1985

University of Minnesota (Pathology), 1991

PhD, University of Minnesota (Pathobiology), 1990

University College, Galway, Ireland (Biochemistry), 1980


Dr. Killeen is Director of Clinical Laboratories at the University of Minnesota Medical Center, Fairview, Vice Chair for Clinical Affairs in the Department of Laboratory Medicine and Pathology, Director of the Advanced Research and Diagnostics Laboratory (ARDL), and a member of the Division of Molecular Pathology and Genomics. He also chairs the College of American Pathologists’ Committee on Laboratory Accuracy Surveys and the Instrumentation Resource Committee. The committee monitors the quality of laboratory assays across the country through the distribution, collection and analysis of proficiency testing specimens and brings problems it identifies to the attention of the clinical pathology community.

Dr. Killeen conducts his clinical research through ARDL, a central laboratory for large-scale clinical trials. He is the Principal Investigator for the central laboratory activities of the Systolic Blood Pressure Intervention Trial (SPRINT), an NIH-funded multi-center, randomized clinical trial designed to test whether a treatment program aimed at reducing systolic blood pressure to a lower goal than currently recommended (<120 mm Hg rather than <140 mm Hg) will reduce cardiovascular disease risk. Some 9,300 research subjects have been enrolled in the seven-year study, which ends in 2018. SPRINT investigators believe the study will provide important information on the risks and benefits of intensive blood pressure treatment targets in a range of high-risk participants including those with prior cardiovascular disease, chronic kidney disease, and those age 75 years or older.



Selected Publications

  • Garimella PS, Lee AK, Ambrosius WT, Bhatt U, Cheung AK, Chonchol M, Craven T, Hawfield AT, Jotwani V, Killeen A, Punzi H, Sarnak MJ, Wall BM, Ix JH, Shlipak MG. Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial. Eur Heart J. 2019 Nov 1;40(42):3486-3493. doi: 10.1093/eurheartj/ehz392.
  • Ginsberg C, Craven TE, Chonchol MB, Cheung AK, Sarnak MJ, Ambrosius WT, Killeen AA, Raphael KL, Bhatt UY, Chen J, Chertow GM, Freedman BI, Oparil S, Papademetriou V, Wall BM, Wright CB, Ix JH, Shlipak MG; SPRINT Research Group. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1816-1824. doi: 10.2215/CJN.05390518.
  • Malhotra R, Craven T, Ambrosius WT, Killeen AA, Haley WE, Cheung AK, Chonchol M, Sarnak M, Parikh CR, Shlipak MG, Ix JH; SPRINT Research Group. Effects of intensive blood pressure lowering on kidney tubule injury in CKD: A longitudinal subgroup analysis in SPRINT. Am J Kidney Dis. 2018 Sep 28. pii: S0272-6386(18)30879-5. doi: 10.1053/j.ajkd.2018.07.015.
  • Danni Li, Angela Radulescu, Rupendra T. Shrestha, Matthew Root, Amy B. Karger, Anthony A. Killeen, James S. Hodges, Shu-Ling Fan, Angela Ferguson, Uttam Garg, Lori J. Sokoll, Lynn A. Burmeister. Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA 2017.;318(12):1150-1160.doi:10.1001/jama.2017.13705.
  • Killeen AA: The Clinical Laboratory in Modern Healthcare. In Kasper D, Fauci A, Longo D, Hauser S, Jameson J, Loscalzo J (eds): Harrison’s Principles of Internal Medicine, 19th Edition, 2015.
  • Ambrosius WT, Sink K, Foy C, Berlowitz D, Cheung AK, Cushman W, Fine L, Goff D, Johnson KC, Killeen AA, Lewis B, Oparil S, Reboussin D, Rocco M, Williamson W, Wright J, Whelton P: The design and rationale of a multi-center clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Trials, 2014, epub DOI: 10.1177/1740774514537404.
  • Killeen AA, Long T, Souers R, Styer P, Ventura CB, Klee GG: Verifying performance characteristics of quantitative analytical systems: calibration verification, linearity, and analytical measurement range. Archives of Pathology and Laboratory Medicine, in press 2014. Killeen AA, Ashwood ER, Styer PE: Recent trends in performance and current status of creatinine assays. Archives of Pathology and Laboratory Medicine, 2013 Apr 137(4):496-502. doi: 10.5858/arpa.2012-0134-CP.
  • Murray JA, McLachlan S, Adams PC, Eckfeldt JH, Garner CP, Vulpe CD, Gordeuk VR, Branter T, Leiendecker-Foster C, Killeen AA, Acton RT, Barcellos LF, Nickerson DA, Beckman KB, McLaren GD, McLaren CE. Celiac disease: association with iron deficiency in Caucasians but not in non-Caucasians. Clinical Gastroenterology and Hepatology. 2013 Feb 12. doi:pii: S1542-3565(13)00186-9. 10.1016/j.cgh.2013.02.009. [Epub ahead of print].Karger A, Killeen AA: Sanctions of clinical laboratories for proficiency testing failure: a 9-year study. Clinical Leadership Management Review 25(2):20-24, 2011.

Invited Lectures

  • Killeen AA and Miller GW: “Calibration, calibration verification, analytical measurement range, and clinically reportable range”. College of American Pathologists Audio-Conference, recorded February, 2008 (for delivery on CAP website).
  • “Chronic Kidney Disease: Clinical and Laboratory Considerations”. Beckman-Coulter Workshop at AACC National Meeting, San Diego, CA, July 2007.
  • “Get up to Speed in Molecular Diagnostics”. Washington G2 Conference, Tampa, FL, Feb 2007.
  • “Chronic Kidney Disease” Workshop at CAP Annual meetings 2005, 2006
  • “Introduction to Molecular Diagnostics” workshop. William Beaumont Seminar, Royal Oak, Michigan. 2002, 2003, 2005. Co-taught with Dr. Domnita Crisan.
  • “Introduction to Molecular Diagnostics”. American Association for Clinical Chemistry. All-day Workshop at National Meeting, Chicago, 2001, 2002, 2003. Co-taught with Dr. Domnita Crisan.
  • “Genetics of Cardiovascular Diseases”. Michigan State Genetics Symposium (Wayne State University), May, 2001.
  • “Implementing New Technology in the Clinical Laboratory”. ASCP/CAP Annual Meeting, San Diego, CA, October, 2000.



  • Laboratory MedicineClinical Trials 

Board Certifications

American Board of Pathology (Clinical and Chemical Pathology); American Board for Clinical Chemistry (Molecular Diagnostics); American Board of Medical Genetics (Clinical Molecular Genetics)